Melanoma Patient Network Europe
Source: Hans Eichler, EMA, on Adaptive Licensing in March 2012
(These) 'adaptive approaches are all based on the premise that knowledge about medicines is not binary but continues to evolve over time. The proposal is to replace the single transition from non-approval to approval with a series of approval stages with iterative phases of evidence gathering and regulatory evaluation.'
Hans Eichler, EMA, on Adaptive Licensing in March 2012
Surviving Melanoma in Europe.
Access to prevention, early detection and effective treatment for all.